Kenya has commenced the rollout of lenacapavir, the first twice-yearly injectable for HIV prevention, administering initial doses in Nairobi’s Kawangware settlement. The launch marks a significant expansion of pre-exposure prophylaxis (PrEP) options in a country with a high HIV burden.
The long-acting drug, developed by Gilead Sciences, reduces the risk of HIV acquisition by over 99.9% when used as prescribed. Health Minister Aden Duale, present at the launch, stated the initiative brings “a moment of hope for thousands of Kenyan families.” The medication will be provided free through public health facilities.
Samson Mutua, 27, received the first injection. Among early recipients is Peace
Comments are closed for this story.